BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 26, 2025
See today's BioWorld
Home
» Forest Gets Complete Response Letter for COPD Drug Daxas
To read the full story,
subscribe
or
sign in
.
Forest Gets Complete Response Letter for COPD Drug Daxas
May 19, 2010
By
Donna Young
As expected by most analysts, Forest Laboratories Inc. and Nycomed GmbH Monday night received a complete response letter for their chronic obstructive pulmonary disease (COPD) drug Daxas (roflumilast). (BioWorld Today)
BioWorld